Rayno Life Science Portfolio Notes- Q3 Earnings in Two weeks
The Rayno Life Science Portfolio is up 20% and later this month we will see important earnings reports from tools and diagnostics companies. Life Science stocks are outperforming the NASDAQ and S&P in 2010. Exact Sciences(EXAS) $8.89 was a high flier for Q3 with the stock tripling from the...
IMMUCOR(BLUD) Cuts Guidance,Economy and Blood Demand Cited-Update 1
Stock is down over 18% at 3p near $16.5 on 7M shares A "Pure Play "Immunohematology Diagnostic Company Immucor announced Fiscal Q1 2011 results yesterday with a revenue shortfall of (9%) on traditional reagents $49.621M vs $54.719M in Fiscal 2010. Total Consolidated Revenues were $83.6M, 1%...
Rayno Life Science Portfolio: Update Tools and Dx
2010 Original Price % Ret. P Price % Recomm 3/29/10 Q2 12/1/10 Ret. Abaxis ABAX 2/2/09 15 79 21.2 27.86 85 CardioV.Sys. CSII 11/5/10 7.15 8.65 21 Celera CRA 3/28/10 7 6.49 5.66 -19 GenProbe GPRO 2/2/09 45 7 46.3 52.77 17 Illumina ILMN 2/2/09 29 35 43.1 61.79 113 Immucor BLUD 4/5/10 20 18.6...
2010 Rayno Life Science Portfolio: Update Biopharma
2010 Price Original P Price % Ret 7/2/10 Recomm 12/1/10 Alexion ALXN 50.45 2/2/09 35 76.24 117 Ardea Biosci RDEA 19.5 2/2/09 12 22.26 85 Amgen AMGN 51.7 2/2/09 55 53.52 -5 Biogen BIIB 49.42 2/2/09 49 65.37 33 Cephalon CEPH 55.95 2/2/09 77 64.26 -16.5 Cubist CBST 20.7 2/2/09 22 20.98 -4.5...
Rayno Life Science Portfolio Update: Biotechs beat the Market
As of the end of Q3, 2010 has been a very good year for biotechnology stocks beating both the S&P (up 2.9% YTD) and the NASDAQ (up 4.9% YTD). However the QQQQ was up 7.75% YTD. The NYSE Arca Biotech Index is up 23.5% YTD and the First Trust Amex Biotech ETF (FBT) is up 22% YTD. Other drug...